The G1/S Restriction Point: Where a Cell Commits to Dividing

Mitogen Dependence Before, Independence After

Early in G1, withdrawing growth factors causes a cell to drop out of the cycle into a resting state. Once the cell passes the restriction point, removing the same signals no longer stops it: the machinery for S phase is already committed.

This transition marks the difference between a controlled, signal-driven decision to divide and autonomous proliferation. Cancers acquire this autonomy by fixing the switch in the on position.

The RB-E2F Bistable Switch

The restriction point behaves like a toggle rather than a dial. When CDK4/6 and then CDK2 phosphorylate RB past a threshold, E2F is released and drives transcription of cyclin E. Cyclin E-CDK2 then phosphorylates more RB, creating a positive feedback loop that locks the cell into S phase.

This bistability makes the decision sharp and hard to reverse, which is useful for a normal cell but dangerous when the threshold is lowered by oncogenic alterations.

The p53 Arrest Arm

Running alongside the RB switch is a stress-responsive arm. DNA damage or oncogene activation stabilises p53, which induces p21 to inhibit CDK2 and hold the cell in G1 until the problem is dealt with or the cell is removed.

Loss of p53 function does not by itself push a cell through the restriction point, but it removes the ability to stop there when something is wrong.

How Cancers Disable the Restriction Point

The switch can be forced by raising CDK4/6 activity (cyclin D or CDK amplification), removing the p16 brake (CDKN2A loss), or eliminating RB itself (RB1 loss). Viral oncoproteins such as HPV E7 achieve the same end by binding and inactivating RB.

Whichever mechanism is used, the outcome is constitutive E2F activity and continuous entry into S phase.

Why This Matters for Interpretation

CDK4/6 inhibitors are, in effect, an attempt to restore the restriction point by preventing RB phosphorylation. Their expected activity depends on RB still being present and functional.

A pathway report that shows restriction-point alterations describes a proliferative mechanism, not a treatment instruction; the clinical meaning depends on tumour type and the full set of co-alterations.

Key Takeaways

• ·The restriction point is the point of no return for cell-cycle entry.
• ·It is enforced by a self-reinforcing RB-E2F switch plus a p53-dependent arrest arm.
• ·Cyclin/CDK amplification, CDKN2A loss and RB1 loss each defeat the switch.
• ·CDK4/6 inhibitors aim to reinstate the control and generally need intact RB.